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A B S T R A C T
The increasing interest in developing tools to predict drug absorption through mucosal surfaces is fostering
the establishment of epithelial cell-based models. Cell-based in vitro techniques for drug permeability assess-
ment are less laborious, cheaper and address the concerns of using laboratory animals. Simultaneously, in
vitro barrier models that thoroughly simulate human epithelia or mucosae may provide useful data to speed
up the entrance of new drugs and new drug products into the clinics. Nevertheless, standard cell-based in vitro
models that intend to reproduce epithelial surfaces often discard the role of mucus in influencing drug per-
meation/absorption. Biomimetic models of mucosae in which mucus production has been considered may not
be able to fully reproduce the amount and architecture of mucus, resulting in biased characterization of per-
meability/absorption. In these cases, artificial mucus may be used to supplement cell-based models but still
proper identification and quantification are required. In this review, considerations regarding the relevance of
mucus in the development of cell-based epithelial and mucosal models mimicking the gastro-intestinal tract,
the cervico-vaginal tract and the respiratory tract, and the impact of mucus on the permeability mechanisms
are addressed. From simple epithelial monolayers to more complex 3D structures, the impact of the presence
of mucus for the extrapolation to the in vivo scenario is critically analyzed. Finally, an overview is provided
on several techniques and methods to characterize the mucus layer over cell-based barriers, in order to inti-
mately reproduce human mucosal layer and thereby, improve in vitro/in vivo correlation.
© 2017.
1. Introduction
Mucosal drug delivery is often foreseen as one of the most conve-
nient, easy and economical ways to deliver drugs to act in the human
body. Mucosal membranes are found in the respiratory tract, the eye,
the female genital tract and the gastrointestinal tract (GI) tract, which
are all exposed to the external environment [1]. Mucosal drug deliv-
ery is potentially suitable to allow both targeting topic conditions as
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well as systemic distribution. However, understanding the histology
and physiological hurdles of mucosae is essential to allow the effec-
tiveness of free drugs and drug delivery systems (DDS).
The GI tract and the endocervix are composed of a simple layer
of columnar epithelial cell, the respiratory tract is covered by a pseu-
dostratified columnar epithelium whereas the vagina, the exocervix
and the buccal mucosa are formed by a stratified squamous epithelium
[2]. Those mucosal surfaces are more or less constricted in function
of their localization, due to different tightness degrees of apical junc-
tions between epithelial cells. Other cell types like ciliated cells [3]
or goblet cells [4] may also compose the mucosa and influence drug
permeability. After crossing the epithelial layer, drugs diffuse through
the extracellular matrix (ECM) at the lamina propria composed of fi-
brous proteins (e.g. collagen, fibronectin, laminin) and proteoglycans,
and bearing immune cells before passing the endothelium and reach-
ing the blood stream [5].
A mucus layer covers all mucosal surfaces and constitutes an im-
portant barrier to drug absorption [6]. Mucus is a viscous gel mainly
composed of water (90% or more) and also of few amounts of salts,
carbohydrates, lipids and mucins. These last glycoproteins are the
main responsible for the formation of a heterogeneous 3D viscoelas-
tic network [6]. The mucus layer has different thickness and differ-
ent turnover rates regarding the anatomical localization, physiopatho-
logic status and interactions with the external environment. The com-
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invasions in order to protect the underlying mucosa but also against
drugs or nanoparticles drug carriers transport [7].
For several decades now, various research groups have attempted
to mimic in the laboratory different mucosal barriers in order to screen
mucosal drug delivery. The most common approach has been the de-
velopment of cell-based in vitro models, mostly as cell monolayers
[8,9]. Cellular models are usually constructed by seeding epithelial
cells on top of semi-permeable membranes made out of polyester or
polycarbonate and mounted in specific cell culture plates, like the
popular Transwell® systems (Corning, NY). The support holding the
membrane separates two compartments, the apical and the basolateral,
and avoids the wicking and mixing of media between them. Some new
and more complex strategies as 3D model, comprising multiple cellu-
lar or acellular layers, or “organ-on-a-chip” have also been proposed
in order to enhance biorelevance of such in vitro tools [10]. Cell-based
in vitro models are generally a compromise between the levels of com-
plexity reflecting the in vivo situation and, what is practicable to re-
produce in the laboratory. The elaboration of the mucus layer with
right amounts or thickness above the mucosa in a Transwell® system
is still a real challenge. Regardless of the mucosal route of adminis-
tration, it is assumed that the presence of the mucus layer impacts the
local action of drugs and their permeability. Many efforts have been
done to develop new DDS able to squeeze through the complex mu-
cus network. Thereby, cell-based models mimicking a mucosal sur-
face should include the mucus layer in order to better resemble phys-
iological conditions and allow a more relevant assessment of novel
DDS. Indeed, the hurdle posed by mucus is often undervalued in vitro,
which could lead to less than optimal drug delivery strategies being
evaluated (and failing) in vivo.
We address in this review how the mucus layer is currently con-
sidered in the context of in vitro mucosal models and how its pres-
ence affects the evaluation and development of new DDS. First, re-
garding each route of administration, we discuss how the mucus layer
is taken into account in the elaboration of cell-based mucosal models.
The oral delivery is preferential and still the most widely used, thus,
the intestinal barrier is the focus of more detailed discussion. The ef-
fect of the mucus layer in in vitro models representing cervico-vagi-
nal, nasal and pulmonary routes is also overviewed. Although attempts
have been carried out for the ocular mucosa, these are not yet conclu-
sive and therefore this will not be discussed [11,12]. Some evidences
on how the mucus layer may influence results of drug permeability are
provided. We then provide useful experimental techniques to identify
and quantify mucus layers, as well as future perspectives on how to
improve in vitro 3D mucosal barrier models.
2. Consideration of mucus layer in cell-based mucosal models
2.1. Gastrointestinal tract
The GI tract stretches from the mouth to the anus and includes
the organs necessary to digest food, to process waste and to absorb
nutrients, as the stomach, the small and the large intestines. The lu-
minal side of the stomach and the small intestine are fully covered
by mucus which maintains a pH gradient from acid in the lumen
to neutral in contact to epithelial cells [13]. As reported by Atuma
et al., this mucus barrier is composed of an outer loosely adherent
layer and an inner strongly adherent layer. The thickness of the ad-
herent layer depends on the secretion rate and its erosion by enzymes
or physical stress [14]. The inner layer is firmly attached to the ep-
ithelial cells thanks to glycoproteins and predominantly the mucin-2
(MUC2) interconnected in hexagonal forms that then assembles in
parallel sheets [15,16]. This viscous and complex mucus network is
determinant against pathogens dissemination. Indeed, commensal and
environmental microbes are immobilized in mucus via mucin binding
which prevents reaching and damaging the underlying epithelium
[17]. Johansson et al. have shown that transgenic mice without pro-
tein mucin type 2 (MUC2−/−) develop rapidly intestinal inflamma-
tion and cancers which can partially explain the importance of mu-
cus against pathogens invasion [18]. However, the mucus layer all
along the GI tract acts also as a chemical and physical barrier against
drug absorption. Its complex composition and organization [19] im-
pairs the transport of several drugs and DDS having completely dif-
ferent physical-chemical properties. Hydrophobic, ionic, enzyme-sen-
sitive or large molecules are typically entrapped or degraded in the
mucus network thus reducing their oral availability [20–22]. Since the
oral route is the most widely used for the administration of drugs,
cell-based mucosal models mimicking the mouth, the stomach and the
small intestine have been developed. Some models were proposed to
represent the buccal mucosa since this route is quite attractive because
of fast drug absorption [23]. However, the presence of the saliva di-
lutes mucus in the mouth [24] and therefore the importance of mu-
cus as a barrier is likely to be weak. Cell-based models mimicking the
buccal mucosa are therefore, not discussed here. In the following, we
provide an overview of available models according to anatomic local-
ization, in particular how the mucus barrier is considered and studied.
2.1.1. Cell-based in vitro models mimicking the gastric mucosa
The stomach mucosa is in contact with the gastric lumen and is
composed of a single-layered columnar epithelium covered by a mu-
cus layer. An acidic gastric juice (pH 1.5–3.5) is also continuously se-
creted in the stomach, composed of pepsin, lipase, hydrochloric acid
and intrinsic factors [25]. The mucus layer in the stomach prevents the
autodigestion of the mucosa and acts as a physical barrier against the
acidic gastric fluid. In contrast to the small intestine mucosa, the mu-
cus in the stomach is produced by several types of mucus-secreting
cells [26]. In addition, the main function of the stomach is to digest
food ingested and transfer it to the small intestine. The absorption rate
of nutrients and drugs is low and only desirable for local action of drug
which may justify the modest number of cell-based gastric models al-
ready developed [27,28].
Human primary gastric epithelial cells have been used to develop
cell-based gastric models [29,30]. Despite the fact that gastric cell
lines are difficult to immortalize, some efforts have been done in that
sense because culture maintenance of primary cells is technically dif-
ficult. Some cell lines are derived from human gastric carcinomas,
namely Hs746t, AGS, NCI-N87 and MKN28, whereas others are de-
rived from normal tissue, such as KATO-III and JOK-1 cell lines
[31,32]. As an example, the MKN28 cell lines have been used for per-
meability studies of dextran-FITC 4 kDa in response to aspirin treat-
ment [33]. Although the cohesion of epithelial cells has been validated
through tight-junction staining, the presence of the mucus layer has
not been taken into account in the study since it is not mucus-produc-
ing cell. Another cell line, the NCI-N87, has been established from hu-
man gastric carcinoma and seems to be the most attractive until now
for developing cell-based models [30,31]. The study of Lemieux et
al. showed the integrity of the monolayer formed with this cell line
through the quantification of the Transepithelial Electrical Resistance
(TEER), which is a quantitative technique to measure the integrity
of tight junctions in cell culture models [34]. The production of mu-
cus over the epithelial monolayer has been showed by electronic mi-
croscopy [35]. Overall, the development of gastric model is not ex-
haustive and this observation is explained by the poor amount of drugs
absorbed in the stomach.
2.1.2. Cell-based in vitro models mimicking the small intestine
The small intestine represents the major site of drug absorption
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acterized by an apical brush border facing the intestinal lumen. The
basolateral side of the epithelium is in contact with the lamina pro-
pria containing blood vessels and lymph nodes. The intestinal mu-
cosa is organized in several levels of infolding resulting in an alter-
nation between villi and crypts [36]. In addition to enterocytes pre-
sent everywhere, goblet cells producing mucus are mainly found on
the villi, whereas Paneth cells, which are immune cells, are found
in the crypt of the mucosa. Moreover, follicle-associated epithelium
(FAE) covering Peyer's patches is also present, as well as microfold
cells (M cells) that are responsible for the transepithelial transport of
pathogens, macromolecules and micro/nanoparticles [37].
Many in vitro intestinal mucosa models have been developed with
various complexity. They are mainly used to screen the permeability
of drugs or DDS following oral administration. Therefore, the com-
mon goal of these models is to closely mimic the architecture and the
functional activity of the small intestine, and be reproducible and eas-
ily handled in the laboratory in order to decrease the number of in
vivo studies and the related ethical considerations. The human colorec-
tal carcinoma cell line Caco-2 is mostly used to study drug absorp-
tion through the intestinal mucosa [36]. Caco-2 cells grown on Tran-
swell® systems form polarized monolayers tightly joined with apical
microvilli but it is not a mucus-secreting cell lines [38]. By consider-
ing an intestinal model only with the Caco-2 cell line, the impact of
the mucus layer on drug transport is completely neglected, despite the
fact that available evidence points to substantial hindering of the trans-
port of drugs or DDS across intestinal mucus [21,39].
2.1.2.1. Intestinal barrier models including the mucus layer
In order to introduce mucus-producing cells in intestinal models,
Lesuffleur et al. established a new cell line termed HT29-MTX which
has differentiated goblet cell-like phenotype [40,41]. Walter et al.
were the first to co-culture absorptive cells (Caco-2) and mucus-pro-
ducing cells (HT29-MTX) using starting ratios of Caco-2/HT29-MTX
of 75/25, 50/50 and 25/75 [42]. They showed that the TEER de-
creased proportionally to the amount of goblet cells present. This ob-
servation was expected since the junctions between goblet cells are
less tight than those established between enterocytes [4,36]. They se-
lected the ratio of 50/50 and showed higher paracellular permeability
of low absorbable hydrophilic drugs (atenolol) on Caco-2/HT29-MTX
co-culture as compared to Caco-2 monoculture cell monolayers. Fur-
ther on, the complete study of Hilgendorf et al. also reported dif-
ferent TEER values in function of initial seeding ratios of Caco-2/
HT29-MTX, namely 90/10, 70/30 and 50/50, as shown in Fig. 1A
[43]. Acidic components of mucus were stained with Alcian blue and
revealed qualitative difference in the staining depending on the ini-
tial seeding density. Moreover, they investigated the impact of these
different seeding ratios on drug transport with different permeability
characteristics. As previously shown, the permeability of a paracel-
lular marker (mannitol) increased accordingly to the amount of
HT29-MTX cells, explained by the decreasing of epithelial resis-
tance. Interestingly, they showed that the permeability of a transcel-
lular marker (antipyrine) was hindered when they used a monoculture
of HT29-MTX. They confirmed the hindrance of the drug in the mu-
cus layer since after washing the cell monolayer with HBSS buffer,
the permeability became similar to that obtained on the monoculture
Caco-2 cell monolayers (Fig. 1B). They highlighted for the first time
the importance of considering the mucus layer on an intestinal model
permeability in order to screen the permeability of compounds with
different physical-chemical properties.
Then, an improvement of the intestinal mucosa models was made
by the inclusion of M cells on the epithelial layer, by culturing the
Caco-2 cell monolayer with Raji B cells derived from a human
Burkitt's lymphoma. The interaction between enterocytes and the sol-
uble mediators released by the lymphocytes led to the partial change
of the phenotype of the Caco-2 cell population into M-cell like cells
[44–46]. This model mimics the FAE which has high transcytosis
capacities. The increase of the permeability of cationic polymeric
nanoparticles on this FAE model compared to Caco-2 monolayer was
observed [47]. Despite the fact that this FAE model can provide a
more predictable tool for drugs associated to DDS, the mucus layer
was not taken into account. Atuma et al. reported that a loosely ad-
herent mucus layer and a strongly adherent mucus layer of approxi-
mately 110 μm and 15 μm, respectively, covered the villi in the whole
jejunum [14]. In order to overcome the lack of mucus of the previ-
ous, our group investigated the utilization of HT29-MTX cells in the
FAE models and proposed a new triple co-culture model. Antunes et
al. demonstrated the presence of mucus using Alcian blue staining [4].
Moreover, the impact of the mucus layer was investigated in perme-
ability studies using insulin associated to chitosan-based nanoparti-
cles. Experimental data showed that the permeability of insulin was
seven times higher on the triple model as compared to Caco-2/Raji B
co-culture cell monolayers. As previously discussed, these values re-
sulted from the lower TEER values for the triple culture, as a conse-
quence of the presence of HT29-MTX cells. Additionally, the pres-
ence of mucus can retain the nanoparticles in contact to the mu-
cosa. The nanoparticles were formed with chitosan which is well-de-
scribed as a mucoadhesive polymer that could delay the diffusion
through the mucus. Furthermore, in contact with the epithelium, it
has the potential to transiently open epithelial tight junctions [48].
The reliability of the model was also confirmed by comparing per-
meability value to ex vivo intestinal permeability in rats. In a second
study, different initial seeding ratios of Caco-2 and HT29-MTX were
tested (90/10, 80/20 and 70/30) and the proportionality between cells
were quantified after 21 days in culture [49]. Surprisingly, ± 90% of
Fig. 1. Influence of the mucus layer on intestinal barrier property. (A) Transepithelial electrical resistance (TEER) decreases with higher initial seeding ratios of HT29-MTX/Caco-2
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cells were Caco-2 positive cells regardless of the initial seeding den-
sity. Since the physiological percentage of goblet cells into the intesti-
nal mucosa is around 10% [50], the ratio 90/10 was selected for fur-
ther experiments. Conversely, Schimpel et al. selected the ratio 70/30
after proving qualitatively that, in this way, complete coverage of the
co-culture with mucus was possibly, contrasting with poorer results
for lower percentage of HT29-MTX [51].
To sum up, the ability of mucus-producing models to impact per-
meability of drugs or DDS encapsulating drugs is not conclusive. In
fact, it seems that it is more a question of impacting tight junctions
following the introduction of goblet cells than the actual mucus bar-
rier effect. This constitutes a major drawback of such models and may
be partially solved by the development of improved intestinal barrier
models producing mucus.
2.1.2.2. New improved intestinal barriers
New and improved intestinal models have been proposed over
the recent years. Other cell types or biomaterials have been integrated
into pre-established intestinal models to reproduce as much as possi-
ble in vitro the human intestinal morphology and features. The consid-
eration of the mucus layer into these new cellular intestinal models is
discussed in this section.
Tridimensional (3D) intestinal models were introduced as alterna-
tive to 2D ones in order to better mimic the functions of living tis-
sues [52]. Indeed, cells within a tissue microenvironment interact dif-
ferently with each other and with the ECM, thus determining the phe-
notype and functionality of enterocytes [53]. Li et al. added an ECM
composed of rat tail collagen and primary mouse embryonic fibrob-
lasts underneath the co-culture of Caco-2 and HT29-MTX (ratio 90/
10) cell monolayers [54]. They demonstrated qualitatively and quan-
titatively that the amount of mucus on this 3D model was higher as
compared to 2D monolayers of Caco-2 cells. However, they did not
compare it to the 2D co-culture model and thus the real benefit of
the model is delicate to prove. In order to develop a model of the in-
flamed intestinal mucosa, Leonard et al. seeded Caco-2 cells on the
top of a matrix of bovine collagen type 1 containing dendritic cells and
macrophages. They showed that the stimulation of Caco-2 cells with
the proinflammatory cytokine IL-1β was accompanied by the produc-
tion of mucus of 12% compared to non-stimulated cells [55]. The
overproduction of mucus following inflammatory process has been
reported for Crohn's disease patients in which hypertrophy of goblet
cells occurs [56]. However, the fact that the Caco-2 cell line is able
to produce mucus, without the contribution of goblet cells is surpris-
ing and we may ask if it is not due to an artifact. In another study,
Pereira et al. used intestinal subepithelial myofibroblasts
(CCD18-Co), which have the phenotype of both fibroblasts and
smooth muscle cells, embedded in a commercially available protein
mixture resembling the basement membrane (Matrigel®) and sup-
porting Caco-2 and HT29-MTX (90/10) cells [57]. The TEER values
of the 3D model were lower than the corresponding 2D model and
closely matched typical in vivo transepithelial resistance [43]. How-
ever, the impact of the 3D conformation on the production of mu-
cus was not investigated in a different way than by the evaluation
of TEER. Regarding those information, 3D cellular intestinal models
have been developed to improve the prediction of drug permeability
but have not shown an improvement of mucus production yet.
Another type of model involves the creation of a 3D small intes-
tine with artificial topography through the utilization of biomaterials.
This consists of building 3D scaffolds to reproduce the same size and
shape of intestinal villi in order to provide a more physiological rel-
evant microenvironment. For example, Lee et al. have reconstructed
the shape of villi with a PLGA scaffold manufactured by 3D print-
ing [58]. Other biomaterials such as poly(dimethylsiloxane) coated
with fibronectin [59], collagen coated with fibronectin [60] or colla-
gen/polyethylene-glycol hydrogel [61,62] have also been used in or-
der to serve as substrate for obtaining Caco-2 cell monolayers. Indeed,
Caco-2 cells can effectively grow and differentiate on these intesti-
nal crypt-like topographies but the importance of the mucus layer was
not considered at that time. In 2014, Costello et al. investigated in de-
tails the production of mucus by Caco-2 and HT29-MTX (ratio 66/33)
cell monolayers on top of a 3D PLGA scaffold [63]. These researchers
detailed by confocal microscopy on the structure of the cell mono-
layer, including the presence of a mucus layer (Fig. 2). Moreover, af-
ter 21 days, the amount of mucus production by HT29-MTX grow-
ing on the 3D PLGA scaffold was higher than that observed for the
2D-co-culture on Transwell® system. They also showed that the mu-
cus production in 2D decreased between 7 and 21 days which was ex-
plained by a rapid growth of the HT29-MTX cells on the Transwell®
inserts that led to a more rapid decline and cessation of mucus produc-
tion. The TEER values were two times higher for the 2D model, which
could also prove the lower production of mucus since it modifies the
epithelial integrity due to less tight junctions. Afterwards, they consid-
ered the utilization of this scaffold to establish microbial niches along
the crypt–villus axis [64].
Chen et al. have also shown the positive impact of mimicking the
villi conformation of the intestine on mucus production. They seeded
Caco-2 cells and HT29-MTX cells (ratio 66/33) on a 3D silk scaf-
fold encompassing primary human intestinal myofibroblasts (H-InMy
Fig. 2. Production of mucus on 3D PLGA scaffold co-cultured of Caco-2 and HT29-MTX cell lines. (A) Confocal imaging of a PLGA scaffold with Caco-2 and HT29-MTX with
staining for nuclei (blue) and actin (green). Images were taken after 21 days of culture. (B) Confocal imaging of slice and 3D z-stacks of scaffolds with staining for nuclei (blue), and
mucus (red). Images were taken after 21 days of culture. Reprinted from [63] copyright 2014 Wiley Periodicals, Inc. (For interpretation of the references to color in this figure legend,
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oFibs) and showed the increased production of mucus [65]. By includ-
ing an ECM into their model, they added another important parameter
of the intestinal mucosa. Whereas these two studies showed interest-
ing results in terms of mucus production, it seems essential to study
these findings alongside permeability studies of several drugs.
Isolated primary intestinal cells and induced pluripotent stem cells
(iPCS) [66,67] have also been considered to establish intestinal mod-
els in vitro. Those cells could offer an alternative source of human in-
testinal cells, but culture conditions are tricky and actually difficult to
envisage for robust in vitro intestinal models. Finally, a new trend in-
tends to reproduce the entire gut-blood barrier by introducing the en-
dothelium layer within in vitro models [68,69]. Until now, no studies
have investigated the impact of the presence of endothelial cells on the
production of mucus.
Through this section, we highlight the extent of the small intestine
models developed and how the production of mucus was considered
(Table 1). The optimal initial seeding density of different cell types is
not yet well-established and its impact on drug permeability neither.
The importance of considering the mucus layer on cell-based intesti-
nal models is dramatically influenced by the goals of the performed
study. Indeed, the intestinal permeability of some drugs, either free or
associated to DDS, is not described as being hindered by the mucus
layer. In this case, the utilization of an intestinal model containing a
well-defined and well-characterized mucus layer is probably not cru-
cial, although the presence of goblet-cells influences the transepithe-
lial resistance. On the other hand, many other sensitive drugs are de-
graded (e.g. proteins) or entrapped (e.g. lipophilic drug) in the intesti-
nal lumen due to numerous interactions with mucus components. Ac-
tive researches are now focusing on the development of muco-adhe-
sive particles (MAP) or mucus-penetrating particles (MPP) allowing
the efficient delivery of drugs which cannot effectively reach the ep-
ithelium mucosa alone. MPP diffuse better than conventional nanopar-
ticles within the mucus matrix and reach faster the epithelial layer
whereas MAP adhere to the mucus layer and consequently increase
the residence time and contact intimacy with the mucosa [6,115]. In
this case, the utilization of a cellular model comprising a mucus layer
with the optimal quantity, thickness and composition will dramatically
determine the issue of these experiments. In order to develop a model
allowing the screening of multiple drug delivery, we may suggest to
always use a mucus-secreting cell model.
Importantly, two characteristics of the mucus in the GI tract has
never been emphasized. The formation of the double-layered mucus of
which the outer layer is loosely adherent and the inner layer is strongly
attached to the mucosa remains a real challenge [65]. The utilization of
cell-based model in 2D and the lack of dynamic culture environment
could explain this observation. The second shortcoming of the mucus
produced by cell-based model is its structure and composition [70].
Some differences between mucus from cell culture and native mucus
have been highlighted as the mesh spacing [71] or the mucin expres-
sion pattern. For instance, the HT29 cell line mostly secrete MUC5AC
instead of MUC2 which is the dominant secreted mucin in the small
intestine [41]. These observations can be explained by the fact that
most cell lines used to construct cell-based models come from tumors
[72]. Therefore, the mucin protein expression can be altered in cancer
cell and consequently affect the mucus produced on the top of these in
vitro models.
2.2. Respiratory tract
The respiratory tract extends from the nasal cavity to the pul-
monary alveoli where exchanges between air and blood occur. The
respiratory tract is divided into two segments: the upper composed
of the nasal cavity, pharynx, and larynx, and the lower RT, which
comprises the trachea, bronchi and lungs. The respiratory epithelium
is formed by a ciliated pseudostratified columnar epithelium where
epithelial, ciliated and goblet-cells coexist. Moreover, mucus-produc-
ing glands are also present and together with the previous forms the
well-known mucociliary escalator that induces a rapid clearance of in-
haled particles. As in the case of other routes of administration, the
role of mucus is to prevent some infections of the underlying mu-
cosa. Cell-based in vitro models have been developed for the nasal
and the bronchial mucosa, as well as the alveoli portion mimicking the
air-blood barrier. Indeed, those sections are responsible for drug ab-
sorption and thereby, cell-based models are useful to develop new in-
haled drugs or DDS [77]. This chapter is focused on the consideration
of the mucus layer in in vitro cell-based models mimicking the RT.
2.2.1. Nasal mucosa models
The nasal route of drug delivery is regarded as having different
and interesting advantages. The nasal mucosa possesses a high vas-
cularization which typically induces rapid and direct blood transporta
Table 1
Comparison of cell-based intestinal models and their consideration of mucus layer.
Cell lines Ratio Caco-2/HT29-MTX Consideration of mucus Ref
Co-culture models Qualitatively Quantitatively
Caco-2 + HT29-MTX 75/25;50/50;25/50 Y Y [42]
Caco-2 + HT29-MTX 90/10;70/30;50/50 Y Y [43]
Caco-2 + HT29-MTX 33/66 Y N [73]
Triple models
Caco-2 + Mice lymphocytes - N N [44]
Caco-2 + Raji B - N N [45,46]
Caco-2 + HT29-MTX + Raji B 90/10 Y N [4]
Caco-2 + HT29-MTX + Raji B 90/10;80/20;70/30 Y N [74]
Caco-2 clone + HT29-MTX + Raji B 90/10;80/20;70/30;60/40;50/50;40/60;30/70;20/80;10/90 Y N [51]
Caco-2 + HT29-MTX + Raji B 90/10 Y N [75]
ECM models
Caco-2 Clone HTB37
+ HT29-MTX + MEFs
90/10 Y Y [54]
Caco-2 clone C2Bbe1 - Y Y [55]
Caco-2
+ HT29-MTX + CCD18-Co
90/10 Y N [57]
Artificial topography models
Caco-2 - N N [59,61,62,76]
Caco-2 + HT29-MTX 66/33 Y Y [63,64]
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tion of permeated drugs. This route of administration is now mainly
investigated to target the central nervous systems by crossing the
blood-brain barrier or for the systemic administration of peptides [78].
However, quick mucociliary clearance (6 mm/min) and the presence
of enzymes can impair drug permeability as already reviewed by
Beule et al. [3]. The thickness of the mucus layer in the nasal cavity is
low (10–15 μm) and divided into the lower thick liquid phase and the
upper gel phase [79]. The nasal mucus thickness is the lowest all over
the body but at the same time, the mucociliary clearance induces the
fastest turnover. Therefore, we can wonder how the mucus layer has
to be considered in nasal cell-based models.
Different primary cells have been isolated from human nasal ep-
ithelial tissues [80]. Kissel et al. developed a primary cell line [81]
and used it to test the permeability of three peptides [82]. However,
they did not demonstrate the production of the mucus layer above the
monolayer and therefore its impact on nasal drug permeability was not
addressed. Furthermore, the culture of primary cells from animal tis-
sues is difficult and rather heterogeneous. The culture of human cells
lines is more convenient and the population considered more homo-
geneous. However, the most well-known nasal cell line, RPMI 2650
cells, is not ciliated not producing mucus [83].
Regarding those information, the effect of the mucus layers on
nasal drug permeability is now mainly studied thanks to human
bronchial cell lines (discussed in the next section). These cell lines are
also used to mimic the bronchi barrier since nasal and respiratory ep-
ithelium present similar features.
2.2.2. Bronchial mucosa models
The administration of multiple drugs through the pulmonary route
has also been considered as a noninvasive route of administration. The
inhalation of peptide or gene, for instance, is a promising alternative
to systemic administration since the pulmonary mucosa is highly vas-
cularized and the absorption area is high [84]. After passing the tra-
chea, drugs or DDS reach the bronchial tree depending on its hydrody-
namic diameter. Two types of cell-based models have been proposed
according to localization and deposition of drug in the lung. There-
fore, the development of epithelial cell layers mimicking the epithe-
lium of the airway/bronchial and of alveolar regions of the lung has
been pursued. The upper (including the nasal mucosa) and lower air-
way epithelia have close histological features, being lined by a mu
cus layer of around 55 μm [85]. Conversely, the mucus layer in the
alveolar region, where gas exchanges occur, is negligible and thereby,
the inclusion of goblet cells or other sources of mucus is not consid-
ered in such cell-based models developed so far.
Commercial bronchi epithelial models with different levels of dif-
ferentiation were developed by MatTek Corp., as the EpiAirway™
model series. These models produce mucus but are composed of pri-
mary cells [86]. Considering drawbacks of using in vitro models made
with primary cells, they are not considered in the present discussion.
Furthermore, different previous reviews have described in detail all
bronchial or alveolar cell lines used to develop lung cellular models
[87–89], whereas here, we selected only bronchial cell lines produc-
ing-mucus and forming tight-junctions, in particular the human airway
epithelial cell line Calu-3.
Contrasting with cell-based intestinal models using the Transwell®
system in a “liquid-covered culture” (LCC) configuration, bronchi
models can also be set up in an “air-liquid interface” (ALI). A
schematic picture of the two methods is represented in Fig. 3A.
Because of these two possible configurations, a wide range of vari-
ations can be found among studies reported in the literature in terms
of barrier integrity and, more important here, of mucus production.
For example, Fiegel et al. highlighted the difference of barrier prop-
erties between Calu-3 cells seeded in LCC or in ALI configuration
[90]. After the incubation of PLGA microparticles loaded with flu-
orescein sodium (paracellular transport marker), they found that the
TEER was lower and thus the permeability was higher for the model
in LCC configuration. Moreover, they showed by acidic glycopro-
teins staining that the model in ALI configuration exhibited a uni-
form mucus layer, contrasting with its absence in the LCC configu-
ration. Thereby, the mucus layer on ALI model can protect the un-
derlined epithelium whereas its absence may cause short-term dam-
age, leading to the increased flux of the paracellular marker in the
LCC configuration. The addition of medium into the apical side can
dilute produced mucus and influence the overall barrier properties.
These observations were also validated by Grainger et al. by using Al-
cian Blue staining [91]. Recently, it was shown by Kreft et al. that af-
ter 3 weeks in culture, Calu-3 maintained in ALI conditions formed
a differentiated pseudostratifed epithelium with positive cell staining
with Alcian Blue [92]. However, cells maintained in LLC configura
Fig. 3. Comparison of bronchi barrier morphology between Calu-3 cells seeded in liquid-cover culture (LCC) or in air-liquid interface (ALI) configuration. (A) Schematic repre-
sentation of the two methods used to develop bronchi model on Transwell® insert. (B) Calu-3 cells culture in LCC or in ALI configuration after three weeks in culture. Haema-
toxylin–eosin and Alcian blue staining (stained blue). Scale bars: 20 μm. Reprinted from Publication [92] permission from Elsevier. (For interpretation of the references to color in
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tion formed only a simple cuboidal epithelium without mucus layer
(Fig. 3B).
Overall, the development of lung model with Calu-3 cells in ALI
configuration seems more appropriate to resemble the native bronchi-
olar epithelium producing a mucus layer. The presence of the mucus
gel on bronchi cell models is crucial since many respiratory diseases
as asthma, chronic obstructive pulmonary diseases or cystic fibrosis
are characterized by the overexpression of mucus and by the obstruc-
tion of mucus glands [93]. Despite these evidences, some authors still
use the LCC configuration to test the permeability of DDS.
Some attempts to improve the classical monoculture model has be
done using a 3D model [94,95] or the “organ-on-a-chip” techniques
[96]. These models were well-characterized in terms of mucus pro-
duction with different methods described in Section 5. However, until
now, all of them were done with primary human cells and the impact
of mucus layer on drugs permeability was not investigated.
2.3. Cervico-vaginal tract
The cervico-vaginal (CV) tract is divided in the vagina and the ec-
tocervix which are composed of a stratified squamous epithelia and,
the endocervix and the body of the uterus composed of a single-lay-
ered columnar epithelia. The two types of epithelia are linked by the
squamocolumnar junction or transformation zone. The profuse vascu-
lar irrigation, the low enzymatic activity, the good mucosal perme-
ability for some compounds (e.g. sex hormones) and the fact that the
vaginal administration avoids the hepatic first-pass clearance make of
this route an attractive alternative for the delivery of proteins, pep-
tides, small interfering RNA (siRNA) and plasmid DNA [85,97–99].
The vaginal administration of several drugs is also considered for the
prophylaxis of bacterial or viral infections and for the treatment of
multiple infections and cancer as well. Contrasting with the GI tract,
the human vaginal mucosa does not contain mucus-producing gob-
let cells [100,101]. The vaginal fluid results from the mixture of en-
dometrial fluid, cervical mucus, tissue transudate, vestibular glands
secretions, immune and epithelial cells, and residues of urine [102].
This fluid is called cervico-vaginal mucus (CVM) and is mainly com-
posed of water, mucin fibers, various electrolytes, bacteria and lipids,
as previously reported for the intestinal mucus [103]. Consequently,
the CV tract is underlying by a discontinuous thin layer of fluid (av-
erage thickness around 50 μm [104]) of a maximal volume of around
1–2 mL [100] and a pH in the range of 3.5–4.5 [105]. However, the
volume, composition, pH and viscosity change according the age,
menstrual cycle and sexual intercourse [106]. These modifications
represent a unique behavior and must be taken into account when con-
sidering vaginal drug administration. Despite this, the CV tract is rec-
ognized as an interesting route for the administration of various drug
since local and systemic drug delivery can potentially be achieved
[107,108]. Human ectocervical epithelial cells [109,110] or immor-
talized humans genital cells (Caski, SiHa, HEC-1A) [111–114] have
been considered to develop vaginal cell-based epithelial models and
used to test the permeability of drugs. None of these cells are mu-
cus-producing cells and therefore, the impact of the mucus layer is not
taken into account. Different commercial models are also available as
the EpiVaginal™ model series (MatTek Corp.), which reconstruct the
multilayered structure of the epithelium and have been used for safety
and permeability studies [115,116]. However, this model does not in-
clude the mucus layer neither.
Overall, the impact of the mucus layer on the penetration of drugs
associated to DDS, through the CV tract can be studied in two differ-
ent ways. First, as previously reviewed by Griessinger et al., multi-
ple techniques have been developed to study the mucus permeation or
the mucus diffusion of DDS [117]. Transwell diffusion system (with-
out cell seeding) [118] and multiple particle tracking [119] are mainly
used. The second strategy is to add native or simulated vaginal fluid
above the reconstructed multiplayer epithelium. This technique will be
explained more deeply in Section 3. Therefore, vaginal permeability
studies using current cell-based models may be generally considered
as incomplete and, thus, require to be performed in combination with
other techniques.
Throughout this whole section, we showed that the impact of the
mucus layer on cell-based models is sometimes neglected. In order to
prove that the development of MAP or MPP brings a real interest in
drug permeability through mucosa, the right in vitro model producing
mucus has to be used. As reviewed by Araújo et al. many surface func-
tionalization strategies have been proposed to enhance mucosal drug
absorption [120]. However, in vitro barrier models used to screen the
transport and the enhancement of permeability with the utilization of
MPP or MAP are not always relevant and the impact of the mucus
layer is too often neglected. These in vitro tools are useful to speed up
the pharmaceutical development of drugs but the more appropriated
model has to be selected to really improve the in vitro-in vivo correla-
tion (IVIVC).
3. Supplementation of cell-based mucosal models with artificial
mucus
Beyond the typical approach of including mucin-producing cells in
cell-based models, as described above, some authors have further con-
sidered adding mucus to pre-formed cell membrane models. Human
native mucus is not easy to obtain and inter-individual variations may
introduce significant bias to the outcome of performed experiments.
Fluids from animal sources can be alternatively considered but, those
of human origin, also present high variability regarding their composi-
tion and 3D architecture that influence the biophysical features of mu-
cus, namely its barrier properties [7,121,122]. Moreover, toxicity is-
sues to cell cultures have been raised for fluids collected from animals
[123]. Thus, mucus-like fluids are mostly considered for such purpose.
Different recipes have been proposed in the literature and those con-
taining or modified with commercially available mucins may be of
particular interest [103,119,123–127].
There are some advantages in using artificial mucus. For instance,
this allows overcoming the lack of mucus-producing ability of most
of the common cell-based membrane models used in drug delivery
studies [8]. Also, the composition of artificial mucosal fluids can be
clearly defined allowing to reduce bias induced by variable qualitative
and quantitative production of mucin-producing cells that are highly
dependent on stimuli during handling [128,129]. Indeed, it is likely
that mucus produced by goblet cell in culture do not actually mimic
native mucus [130]. Also, the amount of mucus originated by using
these mucin-producing cells is meager and typically originates dis-
continuous layers of reduced thickness over cell membranes that may
not be fully representative of the in vivo situation [74]. Using exter-
nal sources of mucus may further abbreviate changes induced to cell
monolayer tightness by the incorporation of cell types presenting dif-
ferent abilities to establish intercellular interactions. For example, our
group has recently shown that various drugs present increased perme-
ability across Caco-2/HT29-MTX co-culture cell monolayers as com-
pared to Caco-2 cell monolayers [131]. These observations have been
justified with the reduced ability of mucus-producing cells to establish
tight-junctions thus leading to a leaky cell monolayer. Indeed, the abil-
ity of mucus to act as a barrier was likely outshined by the enhanced
drug permeation across cell monolayer.
Nevertheless, the use of simulated fluids also presents several
caveats. First off, such practice comprises a clear exaggeration of the
natural mucus barriers present in vivo. Artificial mucus is typically
added on top of cell monolayer models grown on Transwell® (or sim-
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like layer with several millimeters in thickness, contrasting with what
happens at mucosae (from a few to < 0.5 mm, depending mainly on
anatomical sites and physiological conditions [132]). Another issue
has to deal with the properties of used mucins. Commercial mucins
are typically available from various sources and in different types but
substantial processing during purification is known to significantly al-
ter the properties of native glycoproteins [133–135]. This may lead to
modified behavior and performance, namely of barrier properties, of
reconstituted artificial mucus. Indeed, mucus surrogates are not able to
reproduce in detail the absolute biophysical properties of native fluids,
although parallel behavior has been reported, namely for drug and par-
ticle diffusion in native and surrogate pig intestinal mucus [136,137].
Another issue of using commercial mucins relates to the possible onset
of cytotoxicity, namely due to the undesirable presence of compounds
used or originated during processing [138]. This could compromise
the functionality of cell membranes and thus impact on the outcome
of assays. Using optimized processing for obtaining more native-like
mucins could help circumvent discussed limitation but inter-labora-
tory variations and different sources of crude mucus are hard hurdles
to overcome. It should be highlighted that other components of artifi-
cial mucus may also induce toxicity and their effect on cell viability
needs to be assessed.
Different studies using surrogate mucosal fluids, mainly for in-
cluding into pre-established cell monolayer models of permeability,
have been described in the literature. These have been shown useful
in demonstrating the potential of mucus as a barrier to drugs and their
carriers. For example, Teubl et al. proposed an interesting in vitro set-
ting based on the addition of an external mucus-like barrier to hu-
man buccal epithelial TR 146 cell monolayers in order to study the
transport of nanoparticles [139]. The mucus layer was obtained by
pre-preparing films of mucin and glycerol with approximately 71 mg/
cm2 and 14 mg/cm2, respectively, which were placed on top of TR 146
cell monolayers for 24 h before qualitative nanoparticle transport ex
periments. Commercial pig gastric mucin was used as it presented
close chemical and morphological features to mucins obtained from
human saliva and reduced cytotoxicity (as compared to mucin from
bovine submaxillary glands). Microscopy studies were able to show
that an adherent layer of mucin was present on top of cell monolayers
but no data was provided regarding its thickness. The proposed model
was successfully used to demonstrate different behaviors of 200 nm
nanoparticles bearing various surface properties and, in particular, cor-
related well with ex vivo experiments performed using pig buccal mu-
cosa (Fig. 4).
In another report, Boegh et al. developed artificial intestinal mu-
cus by comparing its rheological features with native pig intestinal
mucus [123]. The simulated fluid was also optimized to display low
cytotoxicity to Caco-2 cells and negligibly affect TEER of monolay-
ers of these last cells. The final composition was isoosmolal, with
pH 7.4, and comprised 5% (w/v) pig gastric mucin type II, 0.9% (w/
v) Carbopol® 974P NF, 3.1% (w/v) bovine serum albumin, 0.11% (w/
v) linoleic acid, 0.36% (w/v) cholesterol, 0.18% (w/v) phosphatidyl-
choline and 0.163% (w/w) polysorbate 80 in HEPES buffer (10 mM
HEPES, 1.3 mM calcium chloride, 1.0 mM magnesium sulfate,
137 mM sodium chloride). The artificial mucus was added on top
of Caco-2 monolayers grown in Transwell® systems and permeabil-
ity experiments were conducted using hydrophilic (mannitol, FD4,
FD10 and fluorescein isothiocyanate-bovine serum albumin) and hy-
drophobic (testosterone) compounds. Reduction in apparent perme-
ability (Papp) values varied between 1.2 for mannitol and 6.8 for testos-
terone.
CVM plays an important role in mucosal physiology and its im-
portance in HIV dynamics leading to transmission is considered of
relevance [140,141]. Our group is actively engaged in the develop-
ment of vaginal microbicides, i.e. products able to circumvent lo-
cal male-to-female viral transmission events upon sexual intercourse,
namely those based on nanotechnology [142]. We recently proposed
Fig. 4. Transport studies with a buccal in vitro model in comparison with ex vivo experiments in pig buccal mucosa. The nuclei were stained with Hoechst 33,342 (blue). Confocal
laser scanning microscopy of the model with (a) 200 nm fluorescently-labeled carboxyl-modified polystyrene particles (red) aggregated in the mucus layer of the in vitro model, (b)
200 nm fluorescently-labeled amine-modified polystyrene particles (red), and (c) 200 nm plain polystyrene particles (red) permeated the mucus layer and penetrated into the epithe-
lium (scale bar = 10 μm). Radial light microscopy sections of the oral mucosa to determine the localization of (d) 200 nm fluorescently-labeled carboxyl-modified polystyrene (red),
(e) 200 nm fluorescently-labeled amine-modified polystyrene (red), and (f) 200 nm fluorescently-labeled plain polystyrene particles (red) within the advance model (scale bar = 200
μm). Reprinted from [139], Copyright (2012), with permission from Elsevier. (For interpretation of the references to color in this figure legend, the reader is referred to the web
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the incorporation of a mucus-like fluid in either HEC-1-A or CaSki
cell monolayers in order to better understand the effects of such ad-
ditional barrier in the permeation and epithelial accumulation of the
candidate microbicide drug dapivirine [143]. The aqueous fluid was
modified from Owen & Katz [103] and contained 1.5% (w/v) pig gas-
tric mucin type II, 0.5% (w/v) glucose, 0.351% (w/v) sodium chlo-
ride, 0.2% (w/v) lactic acid, 0.14% (w/v) potassium hydroxide, 0.1%
(w/v) acetic acid, 0.04% (w/v) urea, 0.0222% (w/v) calcium hydrox-
ide, 0.016% (w/v) glycerol and enough amount hydrochloride acid
for pH 4.2. The artificial fluid did not change TEER up to at least
4 h and previous experiments demonstrated similar rheological behav-
ior to native mucus [119]. Experiments using the described models
showed that the presence of mucins had considerable impact in both
the permeability and cell monolayer accumulation of dapivirine, either
in suspension or associated to 170 nm PLGA nanoparticles (Fig. 5)
[143]. For instance, Papp mean values were around 2- to 4-fold lower
in the presence of artificial fluid containing mucin, while drug levels
found associated with cell monolayers dropped 5- to 11-times. These
data highlight the impact of mucus in drug and nanocarriers transport
although, as mentioned above, the proposed models may tend to over-
estimate mucus barrier usually found in vivo.
4. Characterization techniques of mucus layer on cell-based
mucosal models
As discussed above, mucus may substantially influence the behav-
ior of drugs and DDS when present in cell-based models. However,
either when developing or for quality control purposes, it is essential
to characterize the presence and properties of this biological barrier.
In the following, we briefly describe different techniques to identify
or to quantify the production of the mucus layer laid over cells. Fur-
thermore, some methods proposed to measure the thickness of the mu-
cus layer and to remove it to prove its presence and impact on drug
or DDS permeability are also discussed. A summary of the different
techniques used and selected references is presented in Table 2.
4.1. Methods to identify the mucus layer
Three main techniques have been commonly used to identify the
presence of mucus on top of cell-based membranes. The first con-
sists of staining acidic mucus components, namely mucin fibers, with
Alcian blue or Toluidine blue reagents and microscopic observation
[43,55,74]. Such experiments can be simply performed during the
cell model development and/or at the end of the culture process. For
instance, Hilgendorf et al. revealed qualitative differences in staining
results as result of HT29-MTX cells initial seeding densities in co-cul-
tures with Caco-2 [43]. The second qualitative technique is based on
the utilization of scanning (SEM) or transmission (TEM) electron mi-
croscopy. Our group showed by using SEM the presence of mucus
residues over co-culture of Caco-2 and HT29-MTX cells (Fig. 6A)
[57]. Also, Walter et al. showed mucus-secretory granules in the api-
cal side of cells using TEM, as represented in Fig. 6B [42].
The third method applied to the identification of mucus on
cell-based models is by using immunofluorescence with anti-mucin
antibody. Vllasaliu et al. have stained the secretory mucin, MUC-5A,
in bronchial model composed of Calu-3 seeded in ALI configuration
[144]. Chen et al. also showed with this technique that the production
of mucus was higher when Caco-2/HT29-MTX cells where seeded on
a 3D silk scaffold compared to cell seeding in 2D [65]. Fig. 7A shows
that the mucin-type 2 (MUC2), represented in red, is more intense in
the 3D scaffold. Costello et al. have further used anti-MUC2 antibody
and the WGA-Texas Red® antibody to stain the mucus layer [63].
Another strategy to indirectly study the impact of the mucus layer
is to wash cell-based models containing mucus and to analyze the con-
sequences in terms of drug or DDS permeability. In this case, mod-
els are washed with HBSS and stirred [43,145] or washed with acetyl-
cysteine [144] to cleave the disulfide bridges between mucin fibers.
The impact of the mucus layer can be inferred by testing the perme-
ability of drugs or DDS on washed and unwashed models. For in-
stance, Vllasiliu et al. tested the permeability of nanoparticles made of
chitosan on Calu-3 cell model in ALI and LCC configurations. They
showed that the MAP (containing chitosan) induced higher permeabil-
ity of Dextran-FITC on ALI model since this model was covered by a
full mucus layer. Moreover, to confirm that permeability enhancement
was due to the presence of mucus and not due to other factors, they
treated the AIC Calu-3 cells with a mucolytic agent (acetylcysteine)
in order to remove the mucus layer, prior to the application of MAP.
Increased permeability for the model containing mucus as compared
to washed cell-model provided evidence of the impact of the mucus
layer. This technique was also used to prove the impact of the mucus
layer on the permeability of lipophilic drugs such as testosterone. In-
deed, the washing procedure increased the absorption rate of testos-
terone twofold across a monolayer of HT29-MTX cells whereas the
permeability was not modified in the Caco-2 cells monolayer [146].
Interestingly, they also showed that TEER were similar after the wash-
ing step proving the integrity of monolayers.
Fig. 5. Permeability and membrane retention of dapivirine in cell monolayers as modulated by nanoparticles, and in the presence or absence of mucin. Results expressed as the
time-dependent permeability of dapivirine across (A) HEC-1-A and (B) CaSki cell monolayers, and (C) drug retention in cell monolayers after 4 h incubation. Points or columns rep-
resent mean values and vertical bars the SD (n = 3). (*) denotes a significant difference (p < 0.05) when compared to the free drug under the same experimental conditions. Reprinted
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Table 2
Summary of techniques useful in identifying and quantifying mucus on cell-based bar-
rier models.
Qualitative methods Reference









Thickness Alcian Blue + Cross-section [65]
4.2. Methods to quantify the mucus layer
Different quantitative techniques have been proposed to character-
ize in more detail the mucus layer on cell-based models. The measure-
ment of the mucus layer thickness was performed by Chen et al. by
using Alcian blue staining followed by cross-sectioning of cell-based
models [65]. Sections were observed under a light microscope (Fig.
7B) and analyzed with Image J software. This simple yet powerful
technique provides both qualitative and quantitative results in term
of mucus thickness. Furthermore, Chen et al. showed that the thick-
ness of the mucus layer above Caco-2/HT29-MTX cells set-up in 2D
(around 4 μm) was significantly lower than the mucus thickness ob-
tained in the 3D silk scaffold system (approximately 17 μm).
Reverse-transcription polymerase chain reaction (RT-PCR) [22]
and quantitative RT-PCR [65,66] have also been used to quantify the
expression of the MUC2 mRNA. For instance, Chen et al. quantified
with RT-PCR the mRNA expression of MUC2 as well as other im-
portant components like two tight junctions (ZO-1 and E-cadherin)
and the villin protein, according to the time in culture. They showed
that the expression of MUC2 was higher when Caco-2/HT29-MTX
(ratio 66:33) cells were cultured on patterned 3D silk scaffolds in-
stead of 2D Transwell®. This technique is useful but we must be
used with caution since the amount of mRNA does not always reflect
the quantity of the amount of protein actually produced. An interest-
ing experiment would be to quantify the expression of MUC2 mRNA
in function of different culture parameters as the initial goblet cells
seeding or the time in culture. Another useful method encompasses
the quantification of mucus secretion on Transwell® inserts by En-
zyme-linked Lectin Assay (ELLA) [63,65,146]. In practical terms, the
mucus layer is removed in different washing steps, being the com-
plete removal checked with Alcian blue or Toluidine blue staining.
Then, samples are incubated with WGA-peroxidase and O-phenylene-
diamine reagents, and the absorbance is read. Using a standard curve
of porcine mucin, the mucin concentration on cell-based model is
quantified. The last quantitative technique is based on the use of the
periodic acid/Schiff reagent [42,54,55]. The principle of this technique
is the same as Alcian blue or ELLA and consists of stained substances
of mucus as glycoproteins, glycolipids and mucins.
The different qualitative and quantitative techniques described
above are not often used and, even less, used in tandem. Depending
on the goal of the research, the identification of the mucus layer can
be more or less relevant. For example, when a new in vitro model is
developed, it seems crucial to identify and quantify the production of
mucus. Thereby, we have seen that the presence of the mucus layer
influences the robustness of the epithelium through variation of the
TEER and consequently, influences the permeability of drugs. On the
other hand, cell-based models previously optimized are often used to
test the performance of new DDS. However, especially when DDS
are developed to increase the diffusion within the mucus network, the
identification of the mucus layer is still important. This is even truer
since different authors have reported that the behavior of cell-based
models varies among different laboratories. Srinivan et al. identified
many differences of TEER measurements of intestinal and pulmonary
in vitro models between laboratories [34]. Concerning the small in-
testine model, our group has recently showed that the property of the
Transwell® system may completely modify the behavior of the ep-
ithelial barrier [147]. Moreover, as explained in Section 2.3.2, the con-
figuration of Calu-3 cells on Transwell® system also determines mu-
cus production. Overall, the proof that the in vitro barrier models pro-
duce mucus in a consistent way is crucial to their development.
5. Conclusions and future perspectives
In this manuscript, we provided a range of models surrogating mu-
cosa but evidenced that the consideration of a mucus layer is often
neglected. This observation is obviously variable depending on the
route of administration and thus on the attempts to reproduce mu-
cosae in vitro. The intestinal barrier has been studied for a long time
and new promising techniques have been developed. However, their
Fig. 6. Scanning (SEM) or transmission (TEM) electron microscope as qualitative techniques to identify the mucus layer. (A) SEM image obtained from Transwell® with Caco-2
and HT29-MTX cells (ratio 90:10), after 21 days in culture. (B) TEM image obtained from Transwell® with Caco-2 and HT29-MTX cells (ratio 50:50), after 26 days in culture (bar,
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Fig. 7. (A) Confocal microscopy images of immunostaining of mucin protein (MUC-2), tight junction (ZO-1), and nucleus (DAPI) of Caco-2/HT29-MTX (ratio 66:33) cultured on
2D Transwell® and on patterned 3D silk scaffolds, 21 days post cell seeding. MUC2 is visualized as red, ZO-1 as green, and DAPI as blue. Scale bar = 200 μm. (B) Light microscopy
of Alcian blue stained frozen sections across the 2D Transwell® and patterned 3D silk scaffolds. Scale bar = 100 μm [65]. (For interpretation of the references to color in this figure
legend, the reader is referred to the web version of this article.)
reproducibility and robustness are not yet completely defined. Other
models mimicking the mucosa of the cervico-vaginal tract, the respira-
tory tract or the buccal mucosa are not exhaustive since their routes of
administration are less used in practice. Thereby, the number of avail-
able cell lines, for instance, is lower and the development of cell-based
model more tedious.
The consideration of the mucus layer on in vitro mucosal barriers
is not always the case whereas its consideration is crucial in order to
develop new DDS. Nano- or micro-particles are used to protect sen-
sitive active molecules or to increase their permeability. Although a
paradigm still exists between MPP and MAP, they are currently one of
the most attractive solutions to spread up the development of mucosal
drug delivery.
Moreover, the lack of well-characterized models-producing mucus
and their reproducibility is still an issue. In order to demonstrate that
a nanocarrier improves the permeability of an active molecule by in-
creasing its mucus diffusion, a model with the presence and the right
amount of mucus has to be used. The development of in vitro models
which include all the components of the mucosal barrier and obviously
the mucus layer, will presumably help in developing new medicines.
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